Provided by Tiger Fintech (Singapore) Pte. Ltd.

JUNSHI BIO

21.350
-0.050-0.23%
Volume:5.33M
Turnover:112.47M
Market Cap:21.04B
PE:-15.04
High:21.800
Open:21.200
Low:20.600
Close:21.400
Loading ...

HK Movers | Biotech Stocks Jump With JW Therapeutics up 11%

Tiger Newspress
·
29 May

Shanghai Junshi Biosciences - Approval of Supplemental New Drug Application for Ongericimab Injection by Nmpa

THOMSON REUTERS
·
27 May

HK Movers | HK's Biotech Shares Soar. Asymchem up 15%; Laekna up 13%; Ascletis, CanSinoBIO up 9%

Tiger Newspress
·
21 May

Junshi Biosciences Gets Registration Certificate in China for 12th Indication of Melanoma Drug

MT Newswires Live
·
28 Apr

Shanghai Junshi Biosciences - Approval of Supplemental New Drug Application for Toripalimab From Nmpa

THOMSON REUTERS
·
25 Apr

Press Release: Junshi Biosciences Announces 2024 Full Year Financial Results and Provides Corporate Updates

Dow Jones
·
29 Mar

Shanghai Junshi Biosciences Full Year 2024 Earnings: In Line With Expectations

Simply Wall St.
·
29 Mar

Shanghai Junshi Biosciences 2024 Loss Shrinks 44%

MT Newswires Live
·
28 Mar

BRIEF-Shanghai Junshi Biosciences Posts FY Loss Attributable Of RMB1,282 Mln

Reuters
·
27 Mar

Shanghai Junshi Biosciences - as at 31 December 2024, Total Revenue RMB1,948 Mln

THOMSON REUTERS
·
27 Mar

Chinese Shares Rise Despite Dip in Industrial Profit; Zhejiang China Commodities City Jumps 7%

MT Newswires Live
·
27 Mar

BRIEF-Shanghai Junshi Biosciences Gets Approval By HSA For Marketing Of Toripalimab

Reuters
·
26 Mar

Shanghai Junshi Biosciences - Approval by Hsa for Marketing of Toripalimab

THOMSON REUTERS
·
26 Mar

Junshi Biosciences Gets Nod to Market Hepatocellular Carcinoma Drug

MT Newswires Live
·
24 Mar

BRIEF-Shanghai Junshi Biosciences Announces Approval Of Supplemental New Drug Application For Toripalimab

Reuters
·
21 Mar

Shanghai Junshi Biosciences - Approval of Supplemental New Drug Application for Toripalimab in Combination With Bevacizumab by Nmpa

THOMSON REUTERS
·
21 Mar

Junshi Bio Gets China Nod to Trial Advanced Tumor Drug; Hong Kong Shares Down 4%

MT Newswires Live
·
21 Mar

Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Surges 37% Yet Its Low P/S Is No Reason For Excitement

Simply Wall St.
·
03 Mar

Junshi Biosciences' 2024 Loss Narrows

MT Newswires Live
·
28 Feb

Shanghai Junshi Biosciences Malignant Tumpr Drug Gets NMPA's Nod for Clinical Trial

MT Newswires Live
·
06 Feb